site stats

Pethema registry

Web13. okt 2015 · Epidemiologic Registry PETHEMA LMA 2015 March 22, 2024 updated by: PETHEMA Foundation. Epidemiologic Registry of Patients Diagnosed With Acute Myeloid Leukemia (PETHEMA LMA 2015) Epidemiologic and retrospective multicenter registry of all patients diagnosed with de novo or secondary acute myeloid leukemia (AML) in the … Web23. dec 2024 · Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Labrador J, Saiz-Rodríguez M, de Miguel D, de Laiglesia A , ...

Real life outcomes of patients aged ≥75 years old with acute ...

Web12. jan 2024 · We retrospectively analyzed the efficacy and safety of CPX-351 in a real-world setting in 103 patients from 12 French centers, including the evaluation of molecular abnormalities at baseline and minimal residual disease (MRD) in responding patients, compared with a historical data set from Bordeaux-Toulouse DATAML registry. Web1. feb 2024 · From 1999 to 2024, 3487 fit adult patients with unequivocal diagnosis of AML (excluding acute promyelocytic leukemia) [ 38] who received 7 + 3 cytarabine plus anthracycline-based induction were... bakalarka uvod https://bodybeautyspa.org

Real life outcomes of patients aged ≥75 years old with acute

WebSecondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients, and is associated with poor overall survival (OS). We analyze the characteristics, … Web9. dec 2013 · Epidemiologic Registry PETHEMA LMA 2013 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT02006004 Recruitment Status : Completed Web9. máj 2024 · This study aims to analyze the treatment strategies and clinical outcomes of very old APL patients reported to the international PETHEMA registry. Between 1997 and 2024, among 2501 APL cases registered 120 were ≥75 years old. Treatment approaches were: AIDA regimen, 79 patients; ATRA alone, 23; 16, supportive care (SC) and 2, other … arangote

Honduras Pre-Check Enrollment Pre-Check Application Entry …

Category:Cancers Free Full-Text PLZF-RARα, NPM1-RARα, and Other

Tags:Pethema registry

Pethema registry

Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid …

Web5. nov 2024 · Here, we compared clinical outcomes between AZA and DEC in AML patients not eligible for intensive chemotherapy in the epidemiologic PETHEMA registry. Methods: … Web21. máj 2024 · Herein, we analyze the incidence, characteristics, and outcomes of variant APLs reported to the multinational PETHEMA (Programa para el Tratamiento de …

Pethema registry

Did you know?

WebNext–Generation Sequencing (NGS) implementation to perform accurate diagnosis in acute myeloid leukemia (AML) represents a major challenge for molecular laboratories in terms … Web29. mar 2024 · para el Tratamiento de las Hemopatías Malignas (PETHEMA) epidemiologic registry. 2. Materials and Methods 2.1. Study Design and Patients The PETHEMA AML registry (NCT02607059) includes patients diagnosed with AML, regardless of previous treatments. We retrospectively collected the main patient charac-teristics, treatment …

Web21. máj 2024 · Overall, 2961 patients with newly diagnosed APL from Spain, Portugal, Argentina (GATLA group), Uruguay, Colombia, and Poland (PALG group) were reported to the PETHEMA registry. Of them, 66 were coded as lack of genetic diagnosis, resulting in 2895 patients with genetically confirmed APL. WebThis study aims to analyze the treatment strategies and clinical outcomes of very old APL patients reported to the international PETHEMA registry. Between 1997 and 2024, among …

Web13. nov 2024 · We aim to compare retrospectively results of the PLERIFLAG cohort versus historical cohorts of patients salvaged with FLAG-IDA (Fludarabine, Idarubicine, Cytarabine, G-CSF as priming agent), or FLAGO-IDA (Gemtuzumab plus FLAG-IDA) registered in the PETHEMA epidemiologic AML registry (NCT02006004). Webon behalf of PETHEMA Group The hypomethylating agents, decitabine (DEC) and azacitidine (AZA), allowed more elderly acute myeloid leukemia (AML) patients to be treated. However, there are little...

WebNCT04687761. Recruiting. Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old. Conditions: Leukemia, Myeloid, Acute, De Novo, Age More 60yr. NCT05060627.

Web17. feb 2024 · The PETHEMA AML registry (NCT02607059) includes patients diagnosed with AML, regardless of the treatment administered. Patient and disease characteristics, … bakalarky-diplomovkyarango y arango mejiaWeb5. nov 2024 · Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry. Pilar Martínez, MD, *, 1 Tomás Palanques Pastor, *, 2 Jose Luiz Lopez Lorenzo, MD, *, 3 Javier Cornago Navascués, MD, *, 4 Gabriela Rodriguez-Macías, ... bakalarmWebHere, we compared clinical outcomes between AZA and DEC in AML patients not eligible for intensive chemotherapy in the epidemiologic PETHEMA registry. Methods: We included newly diagnosed AML patients treated with AZA (75 mg/m2/d IV or SC days 1–7) or DEC (20 mg/m2/d IV days 1–5) that were not eligible for intensive chemotherapy. arang park orgelWebPekema Name Meaning. Historically, surnames evolved as a way to sort people into groups - by occupation, place of origin, clan affiliation, patronage, parentage, adoption, and even … bakalarkaWebPatients and diagnostic criteria: From I January 1985, to 31 December 1989, 178 patients with symptomatic multiple myeloma aged 70 or more years were entered into a … arangrantWebCreate your Family Tree. Discover your Family History. Build your family tree online ; Share photos and videos ; Smart Matching™ technology bakalarky databazy